This new patent highlights our commitment to building a broad portfolio of intellectual property to protect our EXPAREL franchise by expanding its patent life into 2044,” said Frank D. Lee, chief ...

be used to carry anti-TB drugs. Many of the formulations presented are very similar to others that reach the market with regard to the size of the liposome and its constitution. However ...

PITTSBURGH, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LIPO), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today ...

A key focus of our research is the development of liposome based drug delivery systems (LDS). The LDS represents the most developed and promising form of nanovector, representing more than half of all ...

“We believe our proprietary liposomal drug delivery platform holds significant potential to enhance efficacy and tolerability across various therapeutic areas, including oncology, cancer ...

The Food and Drug Administraton has approved Jiangsu Hengrui Pharma's application for bupivacaine liposome, which is a generic of Pacira BioScience's non-opioid pain drug Exparel. Hengrui is the ...

liposome properties, such as size, surface charge and functionality, can be easily tuned. Polymeric nanocarriers can be categorized based on three drug-incorporation mechanisms. The first includes ...

Lipella Pharmaceuticals (LIPO) announced that U.S. Patent No. 12,138,345 for its proprietary liposomal drug delivery platform will be officially issued by the U.S. Patent and Trademark Office ...